3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
20
Lymphoma, B-Cell
17
Lymphoma, Large B-Cell, Diffuse
16
Lymphoma, Non-Hodgkin
13
Multiple Myeloma
11
Recurrence
10
Burkitt Lymphoma
10
Lymphoma, Mantle-Cell
8
Lymphoma
8
Leukemia, Myeloid, Acute
8
Carcinoma, Hepatocellular
7
Pancreatic Neoplasms
6
Lymphoma, Follicular
6
Leukemia, Lymphocytic, Chronic, B-Cell
6
Neoplasms
5
Leukemia
5
Glioma
5
Colorectal Neoplasms
5
Stomach Neoplasms
4
Leukemia, B-Cell
4
Neoplasm, Residual
3
Nasopharyngeal Carcinoma
3
Melanoma
3
Esophageal Neoplasms
3
Breast Neoplasms
3
Simpson-Golabi-Behmel syndrome
2
Sarcoma, Synovial
2
Sarcoma, Ewing
2
Rhabdomyosarcoma
2
Ovarian Neoplasms
2
Interventions
Temozolomide
130
Radiotherapy
86
Bevacizumab
43
Radiation
31
Carmustine
29
Irinotecan
22
Erlotinib Hydrochloride
22
Magnetic Resonance Spectroscopy
21
Chemotherapy, Adjuvant
20
Surgical Procedures, Operative
15
O(6)-benzylguanine
15
Carboplatin
14
Radiotherapy, Intensity-Modulated
13
Radiotherapy, Conformal
13
sargramostim
12
Sirolimus
9
Imatinib Mesylate
9
Filgrastim
9
Drug Therapy
9
temsirolimus
8
Thalidomide
8
Sorafenib
8
Radiosurgery
8
pembrolizumab
7
motexafin gadolinium
7
aldesleukin
7
Vorinostat
7
Procarbazine
7
Gefitinib
7
Cyclophosphamide
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Gliosarcoma
×
Immunotherapy, Adoptive
×
Clear all
NCT02664363
2023-02-17
ExCeL
Duke University
Phase 1
Terminated
3 enrolled
8 charts